SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (15853)2/22/2005 11:52:19 PM
From: zeta1961  Respond to of 52153
 
Unlike paclitaxel or docetaxel, paclitaxel poliglumex did not sensitize normal skin or gut tissue to radiation

Yeah..fascinating underlined..such a QOL advantage..

Having the PK/PD information in one 'package' is helpful too..wonder how it correlates with what you folks already knew..

I was also struck that primary endpoints are OS with TTP, QOL, etc secondary..I'm happy to take the discussion to the CTIC thread..

thanks!

Zeta